IHAM
RCUS icon

Integral Health Asset Management’s Arcus Biosciences RCUS Stock Holding History

Integral Health Asset Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-300,000
Closed -$2.44M – 88
2025
Q2 		$2.44M Buy
+300,000
New +$2.56M 0.22% 69

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Integral Health Asset Management's RCUS Position: Q3 2025 in Review

Integral Health Asset Management sold out of Arcus Biosciences (RCUS) in Q3 2025, closing a stake of 300,000 shares — an estimated $2.44M sold.

Integral Health Asset Management first reported a position in RCUS in Q2 2025 and held it in 1 quarter. The position peaked at $2.44M in Q2 2025. 190 funds tracked by Wall St. Rank hold RCUS as of Q3 2025.

  • Integral Health Asset Management reported no remaining Arcus Biosciences position as of Q3 2025 after selling out during the quarter.
  • Integral Health Asset Management sold 300,000 Arcus Biosciences shares in Q3 2025, an estimated $2.44M.
  • Integral Health Asset Management first reported a position in Arcus Biosciences in Q2 2025 and held it in 1 quarter.
  • Integral Health Asset Management's Arcus Biosciences position peaked at $2.44M in Q2 2025.
  • 190 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2025.

Based on Integral Health Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.